What Teva-Sucralfate treats: main uses and benefits

Teva-Sucralfate is relevant in conditions characterized by periods of heightened symptoms associated with acute or episodic changes in the upper GI tract. Its core therapeutic domain is applied across areas where additional symptomatic support is needed for ulcers. This medication is relevant for managing symptoms that interfere with daily comfort and are linked to organ-specific functional stress.

Sucralfate is commonly used across conditions presenting with acute episodes, relevant for managing symptoms associated with ulcers, including duodenal ulcers. It is considered relevant in contexts involving heightened systemic burden, especially during phases when symptoms become more noticeable. It assists with maintaining functional stability and supports the patient during difficult episodes by easing distress. The drug contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations.

Sucralfate is used during phases when symptoms become more noticeable, where additional symptomatic support is needed.

Quick Fact: Supports ease of symptoms related to physical discomfort

Regulatory References

1. NIH MedlinePlus overview

Eligibility Profile: Who Can and Cannot Use Teva-Sucralfate

The eligibility profile for Teva-Sucralfate (Sucralfate) is strictly defined by regulatory guidelines, delineating populations for whom use is established, restricted, or contraindicated.

Populations Excluded (Contraindicated): The medicine is strictly contraindicated for patients with a known hypersensitivity to Sucralfate or its components. Furthermore, the product must be administered only by the oral route; intravenous administration is explicitly forbidden due to the risk of fatal complications.

Age and Life Stage Rules: Use is established for adults. Safety and effectiveness have not been established in pediatric patients (under 18 years). Use in older adults requires caution due to the higher likelihood of decreased renal, hepatic, or cardiac function, often necessitating renal function monitoring.

Condition-Based Restrictions: The drug must be used with caution in patients with chronic renal failure or those receiving dialysis due to the specific risk of aluminum accumulation and potential toxicity. Caution is also noted for patients with underlying conditions that predispose to bezoar formation (solid mass) and for individuals with diabetes where episodes of hyperglycemia have been reported.

Reproductive Status: In pregnancy, the drug is permitted only if clearly needed, as adequate and well-controlled human studies are lacking. Caution should be exercised during lactation, as it is unknown if the drug is excreted into human milk.

Interactions with other medicines and products

The principal interaction pattern for Sucralfate is a nonsystemic binding that occurs within the gastrointestinal tract. This action leads to a reduction in the absorption (bioavailability) of several co-administered medicinal products. Affected drugs include Cimetidine, Digoxin, Fluoroquinolone antibiotics, Ketoconazole, L-thyroxine, Phenytoin, Quinidine, Ranitidine, Tetracycline, and Theophylline.

---

Timing-Based Separation

This reduction in systemic exposure is the basis for mandatory timing separation requirements. Official regulatory information states that interacting concomitant medications should be administered 2 hours prior to Sucralfate to eliminate the documented interaction. Specifically, Levothyroxine requires a minimum separation of at least 4 hours. Additionally, antacids should not be taken within 30 minutes before or after the administration of Sucralfate.

---

Aluminum and Population-Specific Cautions

Sucralfate's composition as an aluminum salt is the source of other interactions. Caution is advised for patients with chronic renal failure due to the official risk of aluminum accumulation and subsequent toxicity. Furthermore, co-administration with other aluminum-containing antacids may increase the total body aluminum burden. Finally, an interaction with enteral tube feedings may occur, posing a risk of bezoar formation in susceptible patients.

The drug's mechanism involves a selective physicochemical barrier formation, initiated by a required chemical transformation in an acidic environment ( pH < 4). It forms a dense, sticky polyanion gel that selectively binds to the proteinaceous exudate at the ulcer site. This targeted adherence creates a durable physical shield that restricts mechanical stress and chemical diffusion, facilitating the underlying cellular processes that support the mucosa.

---

The polymer complex actively engages in the neutralization of aggressive digestive factors, primarily through the direct inhibition of the proteolytic enzyme Pepsin and the adsorption of corrosive bile salts. The complexation and inhibition of pepsin, alongside the adsorption of bile salts, lowers the enzymatic and chemical activity of the luminal contents.

---

Beyond physical sealing, the drug provides augmentation of endogenous cytoprotection by stimulating natural defense pathways. It promotes the synthesis of Prostaglandin E2 and enhances the concentration of Growth Factors (EGF/FGF) at the lesion. The resulting stimulation of PGE2 enhances the secretion of protective mucus and bicarbonate (, HCO3^-), thereby augmenting the mucosa's intrinsic defense layers. The localized concentration of growth factors accelerates epithelial cell proliferation and angiogenesis, promoting the necessary cellular events for mucosal repair.

How to Use Teva-Sucralfate: Official Administration Guidelines

Teva-Sucralfate is administered orally and must be taken on an empty stomach to ensure its local action within the gastrointestinal tract. Treatment must be continued for the full prescribed duration, typically 4 to 8 weeks, even if symptoms improve. The oral suspension form must be shaken thoroughly before each use.

Official Dosing Schedule

Treatment Phase (Adults)	Dose	Frequency	Timing in Relation to Meals
Active Duodenal Ulcer	1 gram	Four times per day (QID)	1 hour before or 2 hours after meals
Duodenal Ulcer Maintenance	1 gram	Twice per day (BID)	1 hour before or 2 hours after meals

Special Administration Rules

Separation from Other Agents: To avoid potential interference with absorption, Sucralfate should be taken separately from other oral medications. Separate administration by 2 hours before the sucralfate dose for critical medications like certain antibiotics or antacids. Antacids for pain relief should be separated by at least 30 minutes before or after the dose.

Missed Dose: If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule should be resumed. Do not take a double dose to compensate for a missed one.

Age-Specific Use: Dose selection for elderly patients should be cautious, typically starting at the lower end of the dosing range, reflecting the greater frequency of decreased renal function. The safety and effectiveness of systemic use in pediatric patients have not been established.

Research Evidence / Overview of Studies for Teva-Sucralfate

---

Evidence for Use in Duodenal and Gastric Ulcers

Teva-Sucralfate was studied for use in conditions characterized by fluctuating or episodic manifestations, specifically duodenal and gastric ulcers. Research examined whether the use of the drug was associated with changes in ulcer appearance over defined time intervals. These studies often involved short-term controlled trials where individuals with ulcers were observed in research exploring how symptoms change over time. The main outcomes related to physical discomfort and ulcer size were monitored.

Studies report how symptoms evolved in the observed populations, and research described changes measured during the study period related to ulcer appearance. Data show patterns related to the short-term evolution of the ulcers in the observed populations. However, these results apply only to the populations studied and primarily reflect the acute phase of the conditions.

Evidence for Use in Stress Ulcer Prophylaxis

Research examined the use of Teva-Sucralfate in intensive care and hospital settings to manage the risk of stress-related ulcers and bleeding, which are conditions associated with acute or disruptive episodes. These comparative trials was evaluated in populations facing significant physiological strain. The outcomes monitored physiological strain or stress and focused on changes in episodic or acute changes such as bleeding events.

The research describes that the use of Teva-Sucralfate was associated with patterns related to the frequency of bleeding in these specific high-stress settings. This evidence contributes to the broader evidence landscape for managing the risk of stress-related ulcers in critically ill patients. Subgroup findings are uncertain regarding its use across all different types of critical illness.

---

What is Still Uncertain about Teva-Sucralfate

Evidence highlights what is known — and what is still uncertain — about the use of Teva-Sucralfate. The findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly to the patterns observed in the studies.

There is limited information for long-term outcomes in several key areas of interest, including the continued relief or long-term management after initial treatment. Data for certain groups remain insufficient, particularly for pediatric patients or pregnant populations, meaning the observed profile in these special populations may differ from the general adult population studied.

Key Studies & References

1. A Comparison of Sucralfate and Ranitidine for the Prevention of Upper Gastrointestinal Bleeding in Patients Requiring Mechanical Ventilation (Large Stress Ulcer Prophylaxis Trial)

Common questions about Teva-Sucralfate (FAQ)

---

Q: How long does it take for this drug to start working, and what is its half-life?

A: Official documents state that Teva-Sucralfate is only minimally absorbed into the bloodstream from the digestive tract, meaning its effects are local rather than systemic. The small amount that is absorbed is primarily excreted in the urine. Because the drug acts locally to form a protective barrier over the ulcer, its action is localized to the digestive tract. Clinical benefits, such as symptomatic relief, may vary by individual and typically require the prescribed duration of use.

---

Q: Is the Teva-Sucralfate tablet the same as Carafate?

A: Yes, regulatory documents indicate that Carafate is one of the original brand names for the active ingredient sucralfate. Teva-Sucralfate contains the identical active ingredient. The official product information classifies both as the same type of medicine, a mucosal protective agent.

---

Q: Is it safe to take this drug if I have been taking iron supplements?

A: Official drug interaction information indicates that Teva-Sucralfate may reduce the absorption (bioavailability) of several co-administered medications, including certain iron supplements. Official drug information often details a required separation of at least two hours between the dose of Teva-Sucralfate and other medications to address this potential reduction in absorption.

---

Q: Does it make you sleepy or affect my ability to drive?

A: According to the official product information, possible nervous system side effects include sleepiness, dizziness, and vertigo. Side effects that can occur, such as sleepiness or dizziness, may impact a person’s ability to perform tasks that require full attention, such as driving or operating machinery.

---

Q: Is this medication safe for long-term use (over 6-8 weeks)?

A: Official information regarding maintenance treatment for duodenal ulcer recurrence prevention can indicate use for periods up to 12 months. However, regulatory warnings note that long-term use may cause issues related to aluminum accumulation, such as aluminum encephalopathy or osteomalacia (bone softening), particularly in patients with kidney problems.

---

Q: Is this medication safe for children under 18 years of age?

A: Official product information states that the safety and effectiveness have not been established in pediatric patients (under 18 years). Regulatory documents state that safety and effectiveness have not been established in pediatric patients, and official use for this population is generally not recommended.

---

Q: What is the rationale for taking Teva-Sucralfate on an empty stomach?

A: Official documents describe that the medication is administered on an empty stomach to support its local action. The medicine works by forming an ulcer-adherent protective barrier at the damaged site. Studies show poorer results when the drug is taken after a meal, which suggests that the coating needs to be established before food enters the stomach.

---

Q: Does this drug cause urinary difficulties or increased urination?

A: Official product information for the oral suspension notes that increased urination may be reported in diabetic patients. This is due to the carbohydrate content in the suspension's inactive ingredients, which may lead to episodes of high blood sugar (hyperglycemia) that increase urine output.

---

Q: Does this drug change my stomach acid pH?

A: The official product information indicates that Teva-Sucralfate has minimal acid-neutralizing capacity (roughly 14 to 16 mEq per dose). Regulatory guidance clarifies that the anti-ulcer activity of the drug is not due to a change in bulk gastric pH; its primary function is protective and local.

---

Q: Is the dosing different for gastric ulcers versus duodenal ulcers?

A: Official regulatory documents generally only specify the dosing schedule for the short-term treatment of active duodenal ulcers. While research evidence may exist for other conditions, the specific dosing for gastric ulcers is not typically detailed within the main prescribing information.

How to Store and Dispose of Teva-Sucralfate

Teva-Sucralfate storage and disposal must strictly follow official regulatory guidelines to maintain the product's integrity.

---

Storage Requirements

• Temperature: Both the tablet and oral suspension must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F).
• Handling Constraint: The Sucralfate oral suspension must be protected by the constraint to Avoid Freezing.
• Container: The medication should be kept in a tightly closed container to protect it from the environment.
• Child Safety: All forms of the product must be kept out of reach of children.

---

Disposal Instructions

Unused or expired Teva-Sucralfate should be managed according to local regulations. Official guidance directs against disposal in household waste or wastewater unless specifically advised. Patients should utilize authorized drug take-back programs where available.